MDM2 and Wilson disease: Brigimadlin (BI907828; Boehringer Ingelheim) and milademetan (RAIN-32; RAIN Therapeutics), two MDM2 inhibitors in late developmental stages for LPSs, showed a manageable safety profile and encouraging signs of efficacy in MDM2-amplified WD/DDLPS patients [46].